# Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105

> **NCT05289726** · PHASE2 · UNKNOWN · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 152 (estimated)

## Conditions studied

- Hand and Foot Skin Reaction
- Colorectal Cancer Stage IV

## Interventions

- **DRUG:** Traditional chinese medicine TDX105
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05289726
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-04-18
- **Primary completion:** 2022-07-18
- **Final completion:** 2023-04-18
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2022-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05289726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05289726, "Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05289726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*